摘要
背景:Alport 综合征 (AS) 是由 COL4A3、COL4A4 或 COL4A5 突变引起的疾病,这些基因编码不同的 IV 型胶原链。绝大多数病例表现为遗传性疾病,尽管大约 10% 的病例存在新发突变。 方法:这项非系统评价总结了最近关于 AS 的证据。我们讨论 AS 的遗传和病理生理学、临床表现、组织病理学、诊断方案、常规治疗和疾病的预后标志物。此外,我们用新的 AS 治疗观点总结了实验结果。 结果:整个生物体中胶原异源三聚体合成不足导致多个器官的基底膜 (BM) 受损。因此,该疾病表现为多种疾病,尤其是肾脏、眼部和耳部的改变。此外,平滑肌瘤病和血管异常也可能作为非典型表现存在。在这个框架中,可以根据临床评估、皮肤或肾脏活检和基因筛查进行诊断,后者是标准。尽管已经描述了延缓疾病进展和延长预期寿命的治疗选择,但没有正式批准的 AS 治疗方法。临床前研究中的新治疗靶点包括帕立骨化醇、钠-葡萄糖协同转运蛋白-2 抑制剂、甲基巴多索隆、抗 microRNA-21 寡核苷酸、重组人五聚体-2、赖氨酰氧化酶样-2 阻滞剂、羟丙基-b-环糊精,4-苯基丁酸钠和干细胞疗法。 结论:AS 仍是一种严重漏诊和误诊的疾病。病理生理学仍未完全了解,该疾病的遗传学也有一些空白。目前,AS尚无特效有效的治疗方法。需要进一步研究以建立新颖有效的治疗方案。
关键词: Alport 综合征、基因突变、肾小球基底膜、胶原链、足细胞病、肾素血管紧张素系统、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂。
Current Medicinal Chemistry
Title:Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives
Volume: 28 Issue: 27
关键词: Alport 综合征、基因突变、肾小球基底膜、胶原链、足细胞病、肾素血管紧张素系统、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂。
摘要:
Background: Alport syndrome (AS) is a disease caused by mutations in COL4A3, COL4A4 or COL4A5, the genes that encode distinct chains of type IV collagen. The vast majority of cases present as an inherited disorder, although de novo mutations are present in around 10% of the cases.
Methods: This non-systematic review summarizes recent evidence on AS. We discuss the genetic and pathophysiology of AS, clinical manifestations, histopathology, diagnostic protocols, conventional treatment and prognostic markers of the disease. In addition, we summarize experimental findings with novel therapeutic perspectives for AS.
Results: The deficient synthesis of collagen heterotrimers throughout the organism leads to impaired basement membranes (BM) in several organs. As a result, the disease manifests in a wide range of conditions, particularly renal, ocular and auricular alterations. Moreover, leiomyomatosis and vascular abnormalities may also be present as atypical presentations. In this framework, diagnosis can be performed based on clinical evaluation, skin or renal biopsy and genetic screening, the latter being the gold standard. There are no formally approved treatments for AS, even though therapeutic options have been described to delay disease progression and increase life expectancy. Novel therapeutic targets under pre-clinical investigation included paricalcitol, sodium-glucose co-transporter- 2 inhibitors, bardoxolone methyl, anti-microRNA-21 oligonucleotides, recombinant human pentraxin-2, lysyl oxidase-like-2 blockers, hydroxypropyl-b-cyclodextrin, sodium 4-phenylbutyrate and stem cell therapy.
Conclusion: AS is still a greatly under and misdiagnosed disorder. The pathophysiology is still not fully understood and genetics of the disease also have some gaps. Up to know, there is no specific and effective treatment for AS. Further studies are necessary to establish novel and effective therapeutic protocols.
Export Options
About this article
Cite this article as:
Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives, Current Medicinal Chemistry 2021; 28 (27) . https://dx.doi.org/10.2174/0929867328666210108113500
DOI https://dx.doi.org/10.2174/0929867328666210108113500 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Hendra and Nipah Viruses: Pathogenesis and Therapeutics
Current Molecular Medicine Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Biosafety of Adenoviral Vectors
Current Gene Therapy Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology